Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms - Wikidata - wikimedia - TriplyDB

Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms

Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms

http://www.wikidata.org/entity/Q28165363

about

The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19 The association of four common polymorphisms from four candidate genes (COX-1, COX-2, ITGA2B, ITGA2) with aspirin insensitivity: a meta-analysis Aspirin resistance: an evaluation of current evidence and measurement methods A critical appraisal of the phenomenon of aspirin resistance The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials.Aspirin and clopidogrel resistance: an emerging clinical entity Relationship between endothelial dysfunction, oxidant stress and aspirin resistance in patients with stable coronary heart disease Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin The BC genotype of the VNTR polymorphism of platelet glycoprotein Ibalpha is overrepresented in patients with recurrent stroke regardless of aspirin therapy The effect of acetylsalicylic acid resistance on prognosis of patients who have developed acute coronary syndrome during acetylsalicylic acid therapy Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects.Aspirin resistance: Fact or fiction? A point of view.Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.Searching for factors associated with resistance to acetylsalicylic acid used for secondary prevention of stroke Genetics of platelet glycoprotein receptors: risk of thrombotic events and pharmacogenetic implications.Antiplatelet drug resistance: not ready for prime time.A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass.Impact of genetic polymorphisms on clinical response to antithrombotics.Genetics of coagulation: considerations for cardiac surgery.Pharmacogenomics and the potential for personalized therapeutics in cardiovascular disease.Pharmacogenomics of platelet responsiveness to aspirin.Aspirin resistance: biological and clinical implications.Pharmacogenetics of aspirin resistance: a comprehensive systematic review.Diabetes mellitus: a prothrombotic state implications for outcomes after coronary revascularization Aspirin resistance: disparities and clinical implications.Pharmacogenetics of cardiovascular drug therapy.High on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction.The pharmacogenetics of antiplatelet agents: towards personalized therapy?Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists.The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis.Pharmacogenomics of oral antiplatelet drugs.Anti-platelet therapy in small animal medicine.Antiplatelet Resistance-Does it Exist and How to Measure it?Stroke and aspirin non-responder patients: relation with hypertension and platelet response to adenosine diphosphate.The platelet glycoprotein Ia/IIa gene polymorphism C807T/C873A: a novel risk factor for retinal vein occlusion.Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.[Acetylsalicylic acid non-responders after ischemic insult in geriatric patients].Association of CYP2C19, CYP3A5 and GPIIb/IIIa gene polymorphisms with Aspirin and Clopidogrel Resistance in a cohort of Indian patients with Coronary Artery Disease.

P2860

Q26801867-61CC17B0-8D90-47E3-B4CF-7982738D95E4 Q26860958-ED2AFD74-D306-4532-BC55-9AA32A5DB875 Q28183220-280743E5-F43B-4DF8-84C8-1FECDEC08D8F Q28183919-16506D31-BD58-43DD-A48D-308BA4F9AC44 Q28192919-148C4377-ACCA-4174-AE70-F9C508E783BA Q28194021-2FDCF771-B883-41D2-AA0A-880806A4535F Q28210092-068A1E30-2C2A-40FF-A92E-967B0E0DABD4 Q28212922-6122D4C3-DC74-433C-833E-B9E23E9DA430 Q28218392-AADF51A6-7418-416C-A7F1-3BCC233E4D3E Q28220382-3513CFE4-1D42-4918-805A-394B94A4D365 Q28221437-7EA0185E-7418-4EF9-BE1A-E7EADDFF467F Q34065288-B2B65BB6-68A3-4760-9E29-CBBB3D69023E Q34389630-D0646E2E-0B75-4833-8B38-9BD0AC3C27B3 Q34771381-80119133-274A-4399-9E80-1455487E8D0F Q35232269-602A4CAE-8A8B-49DD-8133-8F5F795B5053 Q36094351-BE2E0D15-8036-4B6A-8137-891838B74D8F Q36289432-2EFABF34-6E93-4C92-9E1A-7B6502C4F350 Q36374457-2942D50F-4CF4-4D53-A7DC-5BFBAF42916F Q36441477-D2CA962B-C0E8-4ADB-8AA3-D1AD6EACB00A Q36697910-5E5AC912-63AA-4EC2-B48A-746F0FD1F049 Q36836583-A259B444-84FE-4F08-9644-8116E0FC5EA7 Q36989841-7283F0FD-6752-476A-8CC5-B2B7264A2F49 Q37089560-2BF02B9E-BCDD-491B-9137-494867BAC6A5 Q37145122-34EC5FA1-EE2C-4FFA-80A7-C8FB6CF0AC5C Q37167506-CA844100-76C1-4AE6-9FA1-779291B48AA3 Q37227512-553A6CF1-55AA-46C7-9A99-76C03A4E0183 Q37430401-BA711300-7B51-4162-8B52-559C19ADB46B Q37680302-0C0E4DAD-8BC3-4651-ADAC-62AD221E65C6 Q37913976-B8FD20BC-A62C-4122-AC46-AE5CE6F37F58 Q38117748-6A32D6D1-0FDB-4E61-82E5-378E2151EB6B Q38120047-F1E3E2ED-C7EB-4E6C-B81C-65CEDC1A5031 Q38195628-4F539EE0-7667-476B-87F1-03BEEFEE9195 Q38770733-1CF66273-F2F4-48A4-BF0D-67A2F37F7563 Q40014803-821AEA8D-8CB8-4825-A5E4-1C4FFF601227 Q43255962-B33D317A-98FB-4556-BAC4-013363C2B487 Q44815015-25FE65DC-AB7C-4AD8-A0C8-753EBFBA479B Q46909934-3E4A2E7D-D698-42AD-9526-DF2C2158B378 Q52881694-BA05FF46-AF8C-483D-9388-15133A2F5602 Q53584028-325A2901-016C-47C9-BDA9-BE93AFA3A4DC

P2860

Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibalpha) polymorphisms

http://www.wikidata.org/entity/Q28165363

description

2003 nî lūn-bûn

@nan

2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Resistance in vitro to low-dos ...... zak (GP Ibalpha) polymorphisms

@ast

Resistance in vitro to low-dos ...... zak (GP Ibalpha) polymorphisms

@en

Resistance in vitro to low-dos ...... zak (GP Ibalpha) polymorphisms

@nl

type

label

Resistance in vitro to low-dos ...... zak (GP Ibalpha) polymorphisms

@ast

Resistance in vitro to low-dos ...... zak (GP Ibalpha) polymorphisms

@en

Resistance in vitro to low-dos ...... zak (GP Ibalpha) polymorphisms

@nl

prefLabel

Resistance in vitro to low-dos ...... zak (GP Ibalpha) polymorphisms

@ast

Resistance in vitro to low-dos ...... zak (GP Ibalpha) polymorphisms

@en

Resistance in vitro to low-dos ...... zak (GP Ibalpha) polymorphisms

@nl

P1433

Q28165363-70E17EB6-4790-4FA9-8956-DAE58F008584

P1476

Q28165363-01084223-C2A5-4E6C-BBA8-DFC0D9933816

P2093

Q28165363-1356760F-2C5D-4B76-B791-E20476809B37

Q28165363-295A7035-3A60-4F54-BC2F-FB5689360DEE

Q28165363-2E98C7CD-EFF1-4036-B970-BAABCFCB7BDC

Q28165363-45525161-BDA7-4E56-AC41-78447F5A9BB1

Q28165363-74336A68-60D9-4EFD-ADA2-75FE0BF1145D

Q28165363-D09F6F9C-BC38-4DFB-8BD3-2B99C47578FE

Q28165363-E03A96FC-8823-4FA8-AB22-688223B83100

Q28165363-F32D33A6-4604-4BA8-BDE1-F9E84A33C653

P304

Q28165363-D6753E2D-4DF2-479A-8BF7-82B6A869DF44

P31

Q28165363-9AA20000-E210-4B58-942B-0E22A5C12339

P356

Q28165363-2AABDE2C-A913-4FD8-BB4E-1F5CC4350B9B

P407

Q28165363-B23F1D58-E2BC-4E54-8AFD-31FF82D25B4B

P433

Q28165363-8D684084-062F-4694-883B-7CB457D22010

P478

Q28165363-3FD0B484-F608-43DF-A4BD-DF7E45F2324D

P577

Q28165363-7E2D6FC1-AE6F-4BF9-BB30-27E271081FE3

P698

Q28165363-7E6505D4-1A02-46C2-A1AE-9BFA5E99335A

P921

Q28165363-BB8336D2-BA4B-4C30-88A7-056DF59C5C2D

P356

S0735-1097(03)00921-5

P1433

Journal of the American College of Cardiology

P1476

Resistance in vitro to low-dos ...... zak (GP Ibalpha) polymorphisms

@en

P2093

André Brizard

http://www.w3.org/2001/XMLSchema#string

Gérard Mauco

http://www.w3.org/2001/XMLSchema#string

Joseph Allal

http://www.w3.org/2001/XMLSchema#string

Laurent Macchi

http://www.w3.org/2001/XMLSchema#string

Luc Christiaens

http://www.w3.org/2001/XMLSchema#string

Nathalie Sorel

http://www.w3.org/2001/XMLSchema#string

Severine Brabant

http://www.w3.org/2001/XMLSchema#string

Stephanie Ragot

http://www.w3.org/2001/XMLSchema#string

P304

1115-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0735-1097(03)00921-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P577

2003-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

13678940

http://www.w3.org/2001/XMLSchema#string

P921